Skip to main content

Table 1 Clinical trials targeting survivin in cancer

From: The twisted survivin connection to angiogenesis

Strategy Pathology Phase Clinical trials identifier
Survivin inhibitors
  YM155 (survivin suppressor) together with Paclitaxel and carboplatin Solid tumors and advanced non-small cell lung carcinoma I/II NCT01100931
  Terameprocol (EM1421), inhibitor of survivin and cdc2 (cyclin-dependent kinase-1) in continuous intravenous infusion Refractory Solid tumors I NCT00664586
  EZN-3042, a locked nucleic acid antisense oligonucleotide Acute Lymphoblastic Leukemia I NCT01186328
  Terameprocol (EM-1421), inhibitor of survivin and cdc2 (cyclin-dependent kinase-1) Leukemia I NCT00664677
  EZN-3042, a survivin-targeted mRNA antagonist, alone or in combination with standard chemotherapy Acute Lymphoblastic Leukemia I NCT01186328
  LY2181308, an antisense oligonucleotid, targeted against survivin mRNA in combination with idarubicin and cytarabine Acute Myeloid Leukemia II NCT00620321
Survivin-based Cellular Therapy
  Dendritic cell vaccine (mRNA from PSA, PAP, survivin and hTERT) plus docetaxel or docetaxel alone Prostate Cancer (castration resistant and metastatic) II NCT01446731
  Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion Melanoma I/II NCT00961844
  Drug: Temozolomide
  Procure®, denditric cells loaded with Survivin-peptide and Telomerase mRNA Ovarian Cancer I NCT01456065
  Dendritic cell loaded with amplified ovarian cancer stem cell mRNA, hTERT/survivin mRNA Ovarian Cancer I/II NCT01334047
  Cell therapy based on dendritic cells transfected with Survivin, hTERT and p53 mRNA Metastatic breast cancer I NCT00978913
Malignant melanoma
  TAA-SPECIFIC CTLs targeting survivin, PRAME, NY-ESO-1, MAGEA4 and SSX Solid Tumors (TACTASOM) I NCT02239861
  Treatment with autologous dendritic cells transfected with Survivin, MelanA and MAGE-A3 mRNA or loaded with MAGE-A3, MelanA and Survivin Melanoma I/II NCT00074230
  Cell therapy with cytotoxic T lymphocytes exposed to tumor associated antigens: NY-ESO-1, MAGEA4, PRAME, Survivin and SSX. Hodgkin or Non-Hodgkin Lymphoma I NCT01333046
  TAA-CTLs may be generated from donors or recipients and will be tested for specificity against 4 tumor antigens commonly found in hematological malignancies (WT1, PRAME, SURVIVIN, and MAGE-A3).   I NCT02203903
Hematological   
Malignancies
  Dendritic cell vaccine (MUC-1 and survivin) in combination with cytokine-induced killer cells Soft Tissue Sarcoma I/II NCT01898663
  Dendritic cell vaccine (MUC-1 and survivin) in combination with cytokine-induced killer cells Renal Cell Carcinoma I/II NCT01924156
  Autologous dendritic cell vaccine (peptides from survivin and telomerase) Renal Cell Carcinoma I/II NCT00197860
  Multiple antigen specific cellular therapy: autologous T cytotoxic cells induced by dendritic cells (loaded with p53, her2, survivin and a total of 17 antigens) Hepatocellular Carcinoma I/II NCT02026362
  Vaccine therapy (p53, survivin and telomerase) with autologous dendritic cells in combination with adjuvant cytokines Advanced Melanoma I/II NCT00197912
  Multiple tumor-associated antigen (TAA)-specific T cells (against WT1, PRAME and survivin) from donors Acute Lymphoblastic Leukemia I NCT02475707
  Multiple tumor-associated antigen (TAA)-specific T cells (against WT1, NY-ESO-1, PRAME and survivin) from donors Acute Lymphoblastic Leukemia/Myelodisplasic Syndrome I NCT02494167
  Multiple tumor-associated antigen (TAA)-specific cytotoxic T cells (against NY-ESO-1, IMAGEA4, PRAME, SSX and survivin) from donors Multiple Myeloma I NCT02291848
Survivin-vaccines
  Survivin peptide vaccination in combination with sargramostin Malignant Glioma I NCT01250470
  Vaccination with DPX-Survivin in combination with low doses of cyclophosphamide (The peptide antigens targeting survivin) Advanced Stage Ovarian, Fallopian or Peritoneal Cancer I/II) NCT01416038
  hTERT/survivin/CMV multipeptide vaccine Breast Cancer Not provided NCT01660529
  Multipeptide vaccination including survivin-peptide Multiple Myeloma I/II NCT00499577
  SurVaxM Vaccine (survivin-peptide vaccine) in combination with temozolamide Glioblastoma II NCT02455557
  Peptide vaccine (IDO/survivine peptide) as enhancer of temozolomide chemotherapy Metastatic Melanoma II NCT01543464
  Vaccine therapy (MART1 analog, gp100 and survivin) and GM-CSF with or without Aldesleukin Melanoma I NCT00470015
  Vaccine therapy (survivin) in patients receiving lenalidomide Multiple Myeloma I NCT02334865
  hTERT tumor vaccine (peptides from telomerase, survivin and cytopeptide) in combination with autologous T cell infusion Multiple Myeloma I/II NCT00834665
  Immunotherapeutic vaccine DPX-Survivac (targeting survivin) in combination with cyclophosphamide Diffuse Large B-Cell Lymphoma II NCT02323230
  Survivin and telomerase peptide vaccination in combination with Daclizumab and Prevnar Advanced Breast cancer I NCT00573495
  Survivin peptide vaccination Advanced Melanoma, pancreatic, colon and cervical cancer I/II NCT00108875